Interpace Biosciences (OTCMKTS:IDXG) Announces Earnings Results

Interpace Biosciences (OTCMKTS:IDXG) posted its quarterly earnings results on Tuesday. The business services provider reported $0.03 earnings per share for the quarter, Zacks reports. Interpace Biosciences had a return on equity of 346.17% and a net margin of 65.25%.The company had revenue of $9.03 million for the quarter.

Interpace Biosciences Price Performance

IDXG remained flat at $1.90 on Thursday. 7,825 shares of the company were exchanged, compared to its average volume of 6,866. Interpace Biosciences has a 52-week low of $0.70 and a 52-week high of $2.40. The company has a market cap of $8.42 million, a PE ratio of -95.00 and a beta of 0.65. The stock’s 50-day simple moving average is $1.91 and its 200-day simple moving average is $1.52.

About Interpace Biosciences

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.